Zoya N. Demidenko Business Profile
Executive Manager at Oncotarget
6666 East Quaker St., Ste. 1A, Orchard Park, New York, United States
(716) 608-1380 https://www.zoominfo.com/p/Zoya-Demidenko/1641948113
When public discuss contemporary medicine, precision plays one of the most crucial roles and human lives are directly dependent on it. Likewise, any researches pertaining to medicine are required to comply with the highest standards. The issue today is that any conclusions of researches can be published online and used as a reference without being precisely verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this issue and tried to generate an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That allows both readers and authors to quality-check publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website provides a full publications list with corresponding scores higher than 100 as well as reports discussed above. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it creates the necessary assistance to anyone, who has interest in oncology.
Oncotarget
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was published back in 2018 by Oncotarget and written by different experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The publication has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Likewise, the paper about melanoma, was used for citations in various news articles 69 times. In addition, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do get helpful scientific facts. Oncotarget is glad to have the chance to share with online readers this highly appreciated and high-quality information, that is trustworthy and reliable.
https://commons.wikimedia.org/wiki/File:Mikhail_(Misha)_V._Blagosklonny,_MD,_Ph.D._with_filter.jpg